300294 博雅生物
已收盘 02-06 15:00:00
资讯
新帖
简况
博雅生物：控股股东华润医药累计增持公司股份6,050,900股
证券之星 · 02-04
博雅生物：控股股东华润医药累计增持公司股份6,050,900股
博雅生物：静注人免疫球蛋白工艺变更提升收得率
证券之星 · 02-02
博雅生物：静注人免疫球蛋白工艺变更提升收得率
港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响
智通财经 · 02-02
港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响
股市必读：博雅生物（300294）预计2025年全年营业收入19.08亿元至21.69亿元
证券之星 · 02-02
股市必读：博雅生物（300294）预计2025年全年营业收入19.08亿元至21.69亿元
博雅生物(300294.SZ)发预减，预计2025年度归母净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%
智通财经 · 01-30
博雅生物(300294.SZ)发预减，预计2025年度归母净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%
华润医药(03320)：华润博雅生物预期年度归母净利润1.05亿元至1.365亿元 同比大幅下降
智通财经 · 01-30
华润医药(03320)：华润博雅生物预期年度归母净利润1.05亿元至1.365亿元 同比大幅下降
华润医药旗下博雅生物预计全年营业收入增长10%至25%
美股速递 · 01-30
华润医药旗下博雅生物预计全年营业收入增长10%至25%
华润医药预计博雅生物全年归母净利润区间为1.05亿元至1.365亿元
美股速递 · 01-30
华润医药预计博雅生物全年归母净利润区间为1.05亿元至1.365亿元
股市必读：博雅生物（300294）1月23日董秘有最新回复
证券之星 · 01-26
股市必读：博雅生物（300294）1月23日董秘有最新回复
博雅生物：公司二级市场股票价格受宏观环境、市场政策、投资者风险偏好等因素影响
证券之星 · 01-23
博雅生物：公司二级市场股票价格受宏观环境、市场政策、投资者风险偏好等因素影响
股市必读：博雅生物（300294）1月16日董秘有最新回复
证券之星 · 01-19
股市必读：博雅生物（300294）1月16日董秘有最新回复
博雅生物：绿十字浆站血浆由绿十字加工生产
证券之星 · 01-16
博雅生物：绿十字浆站血浆由绿十字加工生产
博雅生物：营销团队建设取得显著进展
证券之星 · 01-16
博雅生物：营销团队建设取得显著进展
博雅生物：人血白蛋白等产品已中选广东联盟集采
证券之星 · 01-16
博雅生物：人血白蛋白等产品已中选广东联盟集采
博雅生物（300294）披露持股5%以上股东部分股份质押及解除司法冻结的公告，1月15日股价下跌0.47%
证券之星 · 01-15
博雅生物（300294）披露持股5%以上股东部分股份质押及解除司法冻结的公告，1月15日股价下跌0.47%
博雅生物（300294）股东深圳市高特佳创业投资集团有限公司质押67.8万股，占总股本0.13%
证券之星 · 01-15
博雅生物（300294）股东深圳市高特佳创业投资集团有限公司质押67.8万股，占总股本0.13%
股市必读：博雅生物(300294)股东户数3.08万户，较上期增加2.11%
证券之星 · 01-14
股市必读：博雅生物(300294)股东户数3.08万户，较上期增加2.11%
博雅生物：2024年末存货增长10.54%
证券之星 · 01-13
博雅生物：2024年末存货增长10.54%
博雅生物：薪酬结构含年度绩效与任期激励
中金财经 · 01-06
博雅生物：薪酬结构含年度绩效与任期激励
股市必读：博雅生物（300294）1月5日董秘有最新回复
证券之星 · 01-06
股市必读：博雅生物（300294）1月5日董秘有最新回复
加载更多
公司概况
公司名称：
华润博雅生物制药集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-03-08
主营业务：
华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是白蛋白、免疫球蛋白和凝血因子。公司先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。
发行价格：
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":22.36,"timestamp":1770361425000,"preClose":22.45,"halted":0,"volume":3108600,"delay":0,"changeRate":-0.004,"floatShares":504000000,"shares":504000000,"eps":0.649,"marketStatus":"已收盘","change":-0.09,"latestTime":"02-06 15:00:00","open":22.43,"high":22.56,"low":22.36,"amount":69848500,"amplitude":0.0089,"askPrice":22.37,"askSize":18,"bidPrice":22.36,"bidSize":104,"shortable":0,"etf":0,"ttmEps":0.649,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":22.45,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":24.7,"lowLimit":20.21,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":1.48,"roa":"--","peRate":34.453005,"roe":"4.5%","epsLYR":0.79,"committee":-0.178723,"marketValue":11275000000,"turnoverRate":0.0062,"status":1,"floatMarketCap":11275000000},"requestUrl":"/m/hq/s/300294","defaultTab":"news","newsList":[{"id":"2608336149","title":"博雅生物：控股股东华润医药累计增持公司股份6,050,900股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336149","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608336149?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:52","pubTimestamp":1770209553,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：公司股价长期低迷近5年，严重偏离市场。特别从9.24行情以来，创业板指涨幅超20%，而公司股价跌幅超20%。公司股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400039509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1570","BK0197","300294","BK1191","03320","BK0046"],"gpt_icon":0},{"id":"2608854139","title":"博雅生物：静注人免疫球蛋白工艺变更提升收得率","url":"https://stock-news.laohu8.com/highlight/detail?id=2608854139","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608854139?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:12","pubTimestamp":1770023534,"startTime":"0","endTime":"0","summary":"投资者提问：公司公告显示绿十字（中国）5%静丙已完成二次层析工艺变更并获批。本次静注人免疫球蛋白生产工艺变更的主要内容是由辛酸盐沉淀和二次层析法代替原工艺的离心沉淀法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200024504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"gpt_icon":0},{"id":"2608713839","title":"港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2608713839","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608713839?lang=zh_cn&edition=full","pubTime":"2026-02-02 11:37","pubTimestamp":1770003478,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华润医药跌近3%，截至发稿，跌1.98%，报4.46港元，成交2516.48万港元。公告称，华润博雅生物的血液制品业务受到扩大集采、DRG/DIP改革、医疗保险费用控制及重点监管合理用药等因素影响，导致临床处方减少以及需求下降，与此同时，市场竞争持续加剧，导致报告期内华润博雅生物血液制品业务的毛利率同比下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294","BK0046","VT","03320","BK4585","BK4588","BK1191","BK1570","BK0197","BK0239"],"gpt_icon":0},{"id":"2608889566","title":"股市必读：博雅生物（300294）预计2025年全年营业收入19.08亿元至21.69亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889566","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889566?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:17","pubTimestamp":1769973430,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，博雅生物报收于22.95元，下跌0.86%，换手率1.18%，成交量5.96万手，成交额1.37亿元。博雅生物发布业绩预告，预计2025年全年归属净利润盈利1.05亿元至1.36亿元。公司2025年度业绩预告华润博雅生物制药集团股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为10,500.00万元至13,650.00万元，比上年同期下降65.62%至73.55%；扣除非经常性损益后的净利润为-1,500.00万元至-750.00万元，同比下降102.49%至104.97%。营业收入预计为190,839.48万元至216,863.05万元，同比增长10.00%至25.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"gpt_icon":0},{"id":"2607014663","title":"博雅生物(300294.SZ)发预减，预计2025年度归母净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607014663","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607014663?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:07","pubTimestamp":1769771249,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%;扣除非经常性损益后的净亏损750万元至1500万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"博雅生物(300294.SZ)发预减，预计2025年度归母净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294"],"gpt_icon":0},{"id":"2607163500","title":"华润医药(03320)：华润博雅生物预期年度归母净利润1.05亿元至1.365亿元 同比大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2607163500","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607163500?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:59","pubTimestamp":1769767199,"startTime":"0","endTime":"0","summary":"报告期内，华润博雅生物预期非经常性损益对净利润的影响约为人民币1.2亿元，主要受政府补助、出售资产及财富管理收入等因素影响。截至2024年12月31日止年度，非经常性损益为人民币9500万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294","03320"],"gpt_icon":0},{"id":"1196965835","title":"华润医药旗下博雅生物预计全年营业收入增长10%至25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196965835","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196965835?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:58","pubTimestamp":1769767091,"startTime":"0","endTime":"0","summary":"华润医药集团（股票代码：03320）旗下成员企业博雅生物（股票代码：300294）近日发布业绩预告，预计其本财年营业收入将实现同比增长，增幅区间在10%至25%之间。这一积极预期反映了公司核心业务的稳健发展态势与良好的市场表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1570","BK0197","300294","BK1191","03320","BK0046"],"gpt_icon":0},{"id":"1190881177","title":"华润医药预计博雅生物全年归母净利润区间为1.05亿元至1.365亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190881177","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190881177?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:57","pubTimestamp":1769767030,"startTime":"0","endTime":"0","summary":"华润医药集团发布业绩预告，其旗下子公司博雅生物制药集团预计全年归属于母公司股东的净利润将达到1.05亿元至1.365亿元。这一业绩指引反映了公司在血液制品等核心业务领域的稳健表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0197","300294","BK1191","BK0046","BK0239","03320","BK1570"],"gpt_icon":0},{"id":"2606263550","title":"股市必读：博雅生物（300294）1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606263550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606263550?lang=zh_cn&edition=full","pubTime":"2026-01-26 01:52","pubTimestamp":1769363533,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，博雅生物报收于23.17元，上涨0.74%，换手率1.11%，成交量5.58万手，成交额1.29亿元。董秘最新回复投资者： 请问，截至1月20日，公司股东账户数量多少？公司2026年1月20日含信用账户合并名册的股东人数为30,593户。贵公司作为一个国企，怎么二级市场表现都是几年新低，到底是什么原因董秘： 您好，感谢您对本公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600000812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2605847393","title":"博雅生物：公司二级市场股票价格受宏观环境、市场政策、投资者风险偏好等因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2605847393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605847393?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:18","pubTimestamp":1769159889,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)01月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！贵公司作为一个国企，怎么二级市场表现都是几年新低，到底是什么原因博雅生物回复：您好，感谢您对本公司的关注。公司二级市场股票价格受宏观环境、市场政策、投资者风险偏好等因素影响。公司经营情况请参与公司定期报告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300028372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"gpt_icon":0},{"id":"2604483974","title":"股市必读：博雅生物（300294）1月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604483974","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604483974?lang=zh_cn&edition=full","pubTime":"2026-01-19 03:29","pubTimestamp":1768764548,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，博雅生物报收于23.18元，下跌0.43%，换手率0.69%，成交量3.5万手，成交额8127.03万元。董秘最新回复投资者： 公司近期表示，广东联盟集采价格已落地，但行业利润端普遍承压。当日关注点来自交易信息汇总：1月16日主力资金净流出406.68万元，显示主力短期减持动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900001280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2603396933","title":"博雅生物：绿十字浆站血浆由绿十字加工生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2603396933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603396933?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:00","pubTimestamp":1768554040,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)01月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，绿十字浆站采集的血浆，未来能否在抚州智能工厂进行加工生产？博雅生物回复：您好，感谢您对本公司的关注。根据《血液制品管理条例》等相关规定：单采血浆站只能向一个与其签订质量责任书的血液制品生产单位供应原料血浆，严禁向其他任何单位供应原料血浆。因此，绿十字（中国）下属单采血浆站采集的血浆应当由绿十字（中国）加工生产。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600026968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"gpt_icon":0},{"id":"2603969876","title":"博雅生物：营销团队建设取得显著进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603969876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603969876?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:00","pubTimestamp":1768554039,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物01月16日在投资者关系平台上答复投资者关心的问题。公司在营销团队建设、商业渠道建设、学术推广体系建设等取得了显著进展。团队建设方面，建立了一支专业化、市场化的营销队伍；学术推广方面，已基本覆盖全国主流医院，为产品直达终端提供了有力支持；商业渠道建设方面，与主流商业形成了强强联合、优势互补。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600026971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"gpt_icon":0},{"id":"2603969355","title":"博雅生物：人血白蛋白等产品已中选广东联盟集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2603969355","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603969355?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:00","pubTimestamp":1768554039,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物01月16日在投资者关系平台上答复投资者关心的问题。注意到贵公司高管曾表示“并不担心集采”且公司主力省份暂未纳入试点，但在广东联盟集采中，公司的白蛋白产品未中标。2025年10月，广东省药品交易中心公示了广东联盟双氯芬酸等药品接续采购的拟中选结果，公司产品人血白蛋白、静注人免疫球蛋白、人纤维蛋白原、人凝血因子Ⅷ均已中选。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600026969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"gpt_icon":0},{"id":"2603986874","title":"博雅生物（300294）披露持股5%以上股东部分股份质押及解除司法冻结的公告，1月15日股价下跌0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986874","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986874?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:26","pubTimestamp":1768487174,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，博雅生物报收于23.28元，较前一交易日下跌0.47%，最新总市值为117.39亿元。博雅生物近日发布公告，持股5%以上股东深圳市高特佳创业投资集团有限公司将其持有的677,980股公司股份进行质押，占公司总股本的0.13%，用于融资。同时，高特佳集团此前被司法冻结的227,980股已全部解除冻结，占公司总股本的0.04%。截至公告日，高特佳集团及其子公司累计质押股份38,499,640股，占其持股总数的65.87%，占公司总股本的7.64%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500040948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300294"],"gpt_icon":0},{"id":"2603660674","title":"博雅生物（300294）股东深圳市高特佳创业投资集团有限公司质押67.8万股，占总股本0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603660674","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603660674?lang=zh_cn&edition=full","pubTime":"2026-01-15 18:36","pubTimestamp":1768473362,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物1月15日公开信息显示，股东深圳市高特佳创业投资集团有限公司向苏州诚河清洁设备有限公司、苏州爱普电器有限公司合计质押67.8万股，占总股本0.13%。博雅生物主营业务：公司业务以血液制品为主,生化药、化学药为辅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500032308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"gpt_icon":0},{"id":"2603632429","title":"股市必读：博雅生物(300294)股东户数3.08万户，较上期增加2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603632429","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603632429?lang=zh_cn&edition=full","pubTime":"2026-01-14 03:04","pubTimestamp":1768331053,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，博雅生物报收于23.69元，上涨0.08%，换手率1.36%，成交量6.87万手，成交额1.63亿元。股本股东变化股东户数变动近日博雅生物披露，截至2026年1月9日公司股东户数为3.08万户，较12月31日增加637.0户，增幅为2.11%。户均持股数量由上期的1.67万股减少至1.64万股，户均持股市值为38.5万元。公司2026年1月9日含信用账户合并名册的股东人数为30,763户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400001476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2603063475","title":"博雅生物：2024年末存货增长10.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603063475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603063475?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:57","pubTimestamp":1768291059,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物01月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司2024年末存货大幅增长，且主要构成为原料血浆和在产品。2024年11月公司正式将绿十字（香港）及其下属企业纳入合并报表范围，由于合并报表范围增加，导致合并报表端存货总额较期初明显增长；上市公司母公司2024年末存货增长10.54%，主要系2024年采浆量同比增长导致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300021158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0239","BK0197"],"gpt_icon":0},{"id":"2601896153","title":"博雅生物：薪酬结构含年度绩效与任期激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2601896153","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601896153?lang=zh_cn&edition=full","pubTime":"2026-01-06 18:38","pubTimestamp":1767695939,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物01月06日在投资者关系平台上答复投资者关心的问题。公司2025年半年报显示，多位高管薪酬在百万元以上，但同期公司营收和净利润均出现下滑。公司经理层的薪酬由基本年薪、年度绩效奖金、任期激励、津贴补贴和福利等组成，其中年度绩效奖金、任期激励为浮动薪酬。薪酬水平已参考行业、实际经营情况等因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260106/31919897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300294","BK0239","BK0046","BK0197"],"gpt_icon":0},{"id":"2601834401","title":"股市必读：博雅生物（300294）1月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601834401","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601834401?lang=zh_cn&edition=full","pubTime":"2026-01-06 04:06","pubTimestamp":1767643573,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，博雅生物报收于22.97元，上涨1.64%，换手率0.85%，成交量4.28万手，成交额9767.04万元。董秘最新回复投资者： 董秘，您好！公司公告汇总公司关于参与设立华润医药产业投资基金二期进展暨完成基金备案的公告华润博雅生物制药集团股份有限公司于2025年7月17日召开董事会及监事会，审议通过参与设立华润医药产业投资基金二期的议案，公司以自有资金认缴出资6,000万元人民币，基金规模为10亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600003031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0197","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770476712537,"stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":-0.0316},{"period":"3month","weight":-0.1145},{"period":"6month","weight":-0.1662},{"period":"1year","weight":-0.2238},{"period":"ytd","weight":-0.0106}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32246人(较上一季度增加5.40%)","perCapita":"15637股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":" 华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是白蛋白、免疫球蛋白和凝血因子。公司先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}